

# Impact of Vibration in Older Adults with Parkinson's Disease.

Pretzer-Aboff, I.<sup>1</sup> Elswick, R.K<sup>1</sup>., Watson, A.<sup>2</sup> Sun, M.<sup>3</sup>, Jung, W.<sup>3</sup>, Koltermann, K.<sup>3</sup>, Zhou, G.<sup>3</sup>, & Cloud, L.<sup>1</sup>

### **INTRO**

The RMBand<sup>TM</sup> (Resonate Forward, LLC) is designed to administer a vibration to the wearer's upper arm to decrease or stop tremors in persons with Parkinson's disease (PD).

We hypothesized that the RMBand<sup>TM</sup> would decrease tremors, and the effects of the vibration on tremors would be related to the vibration dose (vibration frequency Hz). We further hypothesized that the vibration delivered would be safe and tolerable for the wearer.

### **METHODS**

# **Study Design**

This was a double blinded two-group randomized trial and was conducted in a single, one-hour session. Thirty PD participants were allocated equally amongst the two groups. Group A received a low-frequency level of vibration, and Group B received a high-frequency level. All participants were exposed to 20 minutes of continuous vibration stimulus. The low and high frequencies were selected based on previous research (Jobges, 2002; Winfree, Pretzer-Aboff, Hilgart, et al., 2013).


Data was collected pre-, during (5 minutes after vibration turned on), and after vibration was turned off to assess lasting effect. Descriptive statistics were used to depict participants. Linear mixed effects model was used to test group effect (low vs. high dose) and effect of each frequency across time (pre-, during, post). Safety and tolerability of the RMBand<sup>TM</sup> was learnt by asking qualitative questions.

Assessments included time in tremor using TremorSense <sup>3</sup> device on wrists, MDS-UPDRS III, Fahn-Tolosa-Marin tremor (F-T-M) rating scale.

#### **RESULTS**


# PARKINSON'S DISEASE TREMORS significantly decrease both during and after vibration

## Rest Tremor Time plot (means and standard errors)



Rest Tremor Percent Model									
Fixed Effect Tests									
Nparm	DF	DFDen	F Ratio	p-value					
1	1	27	0.1509	0.7007					
2	2	54	19.1388	<.0001	$\leftarrow$				
2	2	54	0.1883	0.8289					
	sts Nparm 1	sts Nparm DF 1 1	Nparm DF DFDen 1 1 27 2 2 54	Nparm DF DFDen F Ratio 1 1 27 0.1509 2 2 54 19.1388	Nparm         DF         DFDen         F Ratio         p-value           1         1         27         0.1509         0.7007           2         2         54         19.1388         <.0001				

# **Total** Tremor Time plot (means and standard errors)




All Tremor Percent Model Fixed Effect Tests								
Source	Nparm	DF	DFDen	F Ratio	p-value			
Group	1	1	27	0.0346	0.8539			
Time	2	2	54	22.4077	<.0001	<del>(</del>		
Group*Time	2	2	54	0.6717	0.5151			

## PD Participants:

	Group			_
	Low Dose	High Dose	Pooled	
	Mean (SD)	Mean (SD)	Mean (SD)	<i>p</i> -value
Number years with PD	7.1 (6.2)	6.3 (5.1)	6.7 (5.6)	0.7253*
Age PD Symptoms	59.2 (9.5)	58.1 (12.7)	58.6 (11.0)	0.7840*
Age PD Diagnosed	60.2 (9.6)	61.3 (11.4)	60.7 (10.4)	0.7842*
	N (%)	N (%)	N (%)	
Race				0.3091
Caucasian	15 (100)	14 (93)	29 (97)	
Black	0 (0)	1 (7)	1 (3)	
Hoehn & Yahr Stage				0.0022 <sup>‡</sup>
I	5 (33)	0 (0)	5 (17)	
II	7 (47)	15 (100)	22 (73)	
III	3 (20)	0 (0)	3 (10)	
<b>Deep Brain Stimulator</b>				0.3091 †
Yes	1 (7)	0 (0)	1 (3)	
No	14 (93)	15 (100)	29 (97)	
	Mean (SD)	Mean (SD)	Mean (SD)	
<b>Baseline Tremor Total Score</b>	21.6 (11.3)	18.4 (5.4)	20.0 (8.8)	0.3459*
Baseline MDS-UPDRS Part II	9.3 (6.8)	6.9 (4.1)	8.1 (5.7)	0.2537*
Baseline MDS-UPDRS Part III	8.1 (4.6)	7.8 (2.9)	7.9 (4.1)	0.8132*
<b>Total Daily Dose of Levodopa</b>	595.3 (426.3)	619.0 (594.6)	607.2 (508.5	0.9012*
		_		

<sup>\*</sup> Using a two-sample t-test; <sup>†</sup> using a likelihood ratio test; <sup>‡</sup> using a Fisher's Exact test



### **DISCUSSION**

Percent time with tremor during the pre-vibration period was significantly greater than during- and post-vibration (p<0.0001), for both dose groups. This suggests that vibration therapy applied to the proximal arm may suppress PD tremor.

No significant difference was observed between the high and low dose groups in the MDS-UPDRS part 3 or the FTM tremor scale (p=0.83 and 0.48, respectively). This may be due to the crude nature of these scales.

No significant adverse events related to vibration therapy occurred. <u>In conclusion</u> the RMBand<sup>TM</sup> appears safe and possibly effective for suppression of PD tremor.

Drs. Ingrid Pretzer-Aboff has financial interest in Resonate Forward, LLC, a company with commercial interest in technology. This conflict has been reviewed and managed by VCU.

Funding: This research was funded by Resonate Forward, LLC

<sup>&</sup>lt;sup>1</sup> Virginia Commonwealth University, School of Nursing, & Dept. of Neurology

<sup>&</sup>lt;sup>2</sup> University of Pennsylvania, Precise Center

<sup>&</sup>lt;sup>3</sup> William & Mary College, Computer Science Department, Virginia